Dechert Advises Edge Therapeutics in Merger with PDS Biotechnology

November 29, 2018

Dechert LLP is advising Edge Therapeutics, Inc., a biotechnology company, in connection with its definitive merger agreement with PDS Biotechnology Corporation, a privately-held, clinical-stage cancer immunotherapy company. The merger will result in the creation of a publicly-traded immuno-oncology biotechnology company focused on developing novel products for treating early and late stage cancer, which will retain the PDS name upon the closing of the transaction.

The transaction has been approved by the boards of directors of both companies and is expected to close in the first quarter of 2019, subject to the approval of the stockholders of each company as well as other customary conditions.

The Dechert team advising Edge Therapeutics is led by corporate partner David Rosenthal and includes associates Stephen Pratt, Daniel Mozes, Marie Mast and Dana Maykish.

About Dechert

Dechert is a leading global law firm with 27 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.